📰
Pancreatic ductal adenocarcinoma: the latest breakthroughs
Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.
🤖What changed
Written by AI from the evidence below, every point cited
2026-10-26
Phase 3 PANOVA‑3 trial results combining Tumor Treating Fields with gemcitabine + nab‑paclitaxel in front‑line locally‑advanced pancreatic adenocarcinoma were posted in early 2026.
- The PANOVA‑3 phase 3 trial evaluated TTFields (150 kHz) plus gemcitabine and nab‑paclitaxel as front‑line therapy for locally‑advanced pancreatic adenocarcinoma.
If effective, this could add a non‑chemical modality to improve outcomes beyond standard chemotherapy. NCT03377491 - A phase 3 study of romiplostim for chemotherapy‑induced thrombocytopenia included patients with pancreatic cancer and posted results in February 2026.
Positive findings could reduce treatment interruptions and bleeding risk, enhancing patients’ ability to receive full chemotherapy courses. NCT03362177 - The FDA label for gemcitabine was updated in July 2026.
Label changes may reflect new safety information or dosing guidance that clinicians need to incorporate into practice. Gemcitabine (AVGEMSI, 2026-07-27) - The FDA label for capecitabine was updated in July 2026.
Updated labeling can affect prescribing decisions and monitoring requirements for patients with pancreatic cancer who receive this agent. Capecitabine (capecitabine, 2026-07-21) - The FDA label for olaparib was updated in July 2025.
Changes may expand or refine the use of this PARP inhibitor in patients with germline BRCA‑mutated pancreatic cancer. Olaparib (Lynparza, 2025-07-10)
What to watch next
- Long‑term overall survival and quality‑of‑life data from the PANOVA‑3 TTFields trial (NCT03377491)
- Further safety and efficacy analyses of romiplostim for thrombocytopenia in pancreatic cancer patients (NCT03362177)
💛 ['A recent phase\u202f3 study (PANOVA‑3) has reported results on adding Tumor Treating Fields to standard chemotherapy for locally‑advanced pancreatic cancer, which may offer a new treatment option pending detailed outcomes.', 'Updates to the official labels of gemcitabine, capecitabine, and olaparib mean that doctors now have the latest safety and usage information for these drugs.']
🤖Written by AI from the public sources cited on this page. It may be incomplete or wrong, it is not medical advice, and it does not know you. Discuss it with your doctor before making any decision. Terms of use
HealthTeky